English | 中文

Hudson product information:



Hudson Cata#: HB0031

Product Name: Bicalutamide

CAS#: 16506-27-7 (Free base)

Chemical Formula: N/A

Exact Mass: N/A

Molecular Weight: N/A

Purity: N/A

Storage Info: N/A

Synonym: N/A

 

Structure Formula:
Price:

Structure Formula Not Available.

N/A

Product Info::

According to http://en.wikipedia.org/wiki/Bicalutamide, Bicalutamide (marketed as Casodex, Cosudex, Calutide, Kalumid) is an oral non-steroidal anti-androgen used in the treatment of prostate cancer and hirsutism. It was first launched in 1995 as a combination treatment (with surgical or medical castration) for advanced prostate cancer and subsequently launched as monotherapy for the treatment of earlier stages of the disease. Bicalutamide is marketed by AstraZeneca with the brand names Casodex and Cosudex. It is recommended 50 mg once daily in combination with a luteinizing hormone-releasing hormone analogue or surgical castration.

If you want to make an order, please contact 1 (732) 640-2533

or email wzhuang@hudsonbiopharma.com

 

References (Review papers):

1: Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell KL, Rugo H, Nabell L, Forero-Torres A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri D, Patil S, Feigin KN, Hudis CA, Traina TA. Phase II Trial of Bicalutamide in Patients with Androgen Receptor Positive, Hormone Receptor Negative Metastatic Breast Cancer. Clin Cancer Res. 2013 Aug 21. [Epub ahead of print] PubMed PMID: 23965901.

2: Li YF, Zhang SF, Zhang TT, Li L, Gan W, Jia HT, Xie S, Ji HH, He DL. Intermittent tri-weekly docetaxel plus bicalutamide in patients with castration-resistant prostate cancer: a single-arm prospective study using a historical control for comparison. Asian J Androl. 2013 Aug 19. doi: 10.1038/aja.2013.89. [Epub ahead of print] PubMed PMID: 23955552.